vs

Side-by-side financial comparison of Align Technology (ALGN) and Dexcom (DXCM). Click either name above to swap in a different company.

Dexcom is the larger business by last-quarter revenue ($1.3B vs $1.0B, roughly 1.2× Align Technology). Dexcom runs the higher net margin — 21.2% vs 10.8%, a 10.4% gap on every dollar of revenue. On growth, Dexcom posted the faster year-over-year revenue change (21.6% vs 6.2%). Over the past eight quarters, Dexcom's revenue compounded faster (12.0% CAGR vs 0.6%).

Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandib...

Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.

ALGN vs DXCM — Head-to-Head

Bigger by revenue
DXCM
DXCM
1.2× larger
DXCM
$1.3B
$1.0B
ALGN
Growing faster (revenue YoY)
DXCM
DXCM
+15.4% gap
DXCM
21.6%
6.2%
ALGN
Higher net margin
DXCM
DXCM
10.4% more per $
DXCM
21.2%
10.8%
ALGN
Faster 2-yr revenue CAGR
DXCM
DXCM
Annualised
DXCM
12.0%
0.6%
ALGN

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
ALGN
ALGN
DXCM
DXCM
Revenue
$1.0B
$1.3B
Net Profit
$112.8M
$267.3M
Gross Margin
70.8%
62.9%
Operating Margin
13.6%
25.6%
Net Margin
10.8%
21.2%
Revenue YoY
6.2%
21.6%
Net Profit YoY
21.0%
153.6%
EPS (diluted)
$1.57
$0.67

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALGN
ALGN
DXCM
DXCM
Q1 26
$1.0B
$1.3B
Q4 25
$1.0B
$1.3B
Q3 25
$995.7M
$1.2B
Q2 25
$1.0B
$1.2B
Q1 25
$979.3M
$1.0B
Q4 24
$995.2M
$1.1B
Q3 24
$977.9M
$994.2M
Q2 24
$1.0B
$1.0B
Net Profit
ALGN
ALGN
DXCM
DXCM
Q1 26
$112.8M
$267.3M
Q4 25
$135.8M
$267.3M
Q3 25
$56.8M
$283.8M
Q2 25
$124.6M
$179.8M
Q1 25
$93.2M
$105.4M
Q4 24
$103.8M
$151.7M
Q3 24
$116.0M
$134.6M
Q2 24
$96.6M
$143.5M
Gross Margin
ALGN
ALGN
DXCM
DXCM
Q1 26
70.8%
62.9%
Q4 25
65.3%
62.9%
Q3 25
64.2%
60.5%
Q2 25
69.9%
59.5%
Q1 25
69.5%
56.9%
Q4 24
70.0%
58.9%
Q3 24
69.7%
59.7%
Q2 24
70.3%
62.4%
Operating Margin
ALGN
ALGN
DXCM
DXCM
Q1 26
13.6%
25.6%
Q4 25
14.8%
25.6%
Q3 25
9.7%
20.1%
Q2 25
16.1%
18.4%
Q1 25
13.4%
12.9%
Q4 24
14.5%
17.0%
Q3 24
16.6%
15.3%
Q2 24
14.3%
15.7%
Net Margin
ALGN
ALGN
DXCM
DXCM
Q1 26
10.8%
21.2%
Q4 25
13.0%
21.2%
Q3 25
5.7%
23.5%
Q2 25
12.3%
15.5%
Q1 25
9.5%
10.2%
Q4 24
10.4%
13.6%
Q3 24
11.9%
13.5%
Q2 24
9.4%
14.3%
EPS (diluted)
ALGN
ALGN
DXCM
DXCM
Q1 26
$1.57
$0.67
Q4 25
$1.88
$0.67
Q3 25
$0.78
$0.70
Q2 25
$1.72
$0.45
Q1 25
$1.27
$0.27
Q4 24
$1.40
$0.37
Q3 24
$1.55
$0.34
Q2 24
$1.28
$0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALGN
ALGN
DXCM
DXCM
Cash + ST InvestmentsLiquidity on hand
$1.1B
$917.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$4.1B
$2.7B
Total Assets
$6.3B
$6.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALGN
ALGN
DXCM
DXCM
Q1 26
$1.1B
$917.7M
Q4 25
$1.1B
$917.7M
Q3 25
$1.0B
$1.8B
Q2 25
$901.2M
$1.2B
Q1 25
$873.0M
$904.9M
Q4 24
$1.0B
$606.1M
Q3 24
$1.0B
$621.2M
Q2 24
$761.4M
$939.2M
Stockholders' Equity
ALGN
ALGN
DXCM
DXCM
Q1 26
$4.1B
$2.7B
Q4 25
$4.0B
$2.7B
Q3 25
$4.0B
$2.7B
Q2 25
$3.9B
$2.6B
Q1 25
$3.8B
$2.3B
Q4 24
$3.9B
$2.1B
Q3 24
$3.9B
$2.0B
Q2 24
$3.8B
$2.4B
Total Assets
ALGN
ALGN
DXCM
DXCM
Q1 26
$6.3B
$6.3B
Q4 25
$6.2B
$6.3B
Q3 25
$6.2B
$7.5B
Q2 25
$6.2B
$7.3B
Q1 25
$6.1B
$6.8B
Q4 24
$6.2B
$6.5B
Q3 24
$6.4B
$6.4B
Q2 24
$6.2B
$6.8B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALGN
ALGN
DXCM
DXCM
Operating Cash FlowLast quarter
$151.0M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
1.34×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALGN
ALGN
DXCM
DXCM
Q1 26
$151.0M
Q4 25
$223.2M
$294.0M
Q3 25
$188.7M
$659.9M
Q2 25
$128.7M
$303.0M
Q1 25
$52.7M
$183.8M
Q4 24
$286.1M
$301.4M
Q3 24
$263.7M
$199.5M
Q2 24
$159.8M
$279.4M
Free Cash Flow
ALGN
ALGN
DXCM
DXCM
Q1 26
Q4 25
$187.3M
$192.1M
Q3 25
$169.0M
$579.4M
Q2 25
$107.2M
$208.9M
Q1 25
$27.4M
$96.8M
Q4 24
$263.1M
$176.8M
Q3 24
$233.9M
$88.3M
Q2 24
$106.4M
$213.3M
FCF Margin
ALGN
ALGN
DXCM
DXCM
Q1 26
Q4 25
17.9%
15.3%
Q3 25
17.0%
47.9%
Q2 25
10.6%
18.1%
Q1 25
2.8%
9.3%
Q4 24
26.4%
15.9%
Q3 24
23.9%
8.9%
Q2 24
10.3%
21.2%
Capex Intensity
ALGN
ALGN
DXCM
DXCM
Q1 26
Q4 25
3.4%
8.1%
Q3 25
2.0%
6.7%
Q2 25
2.1%
8.1%
Q1 25
2.6%
8.4%
Q4 24
2.3%
11.2%
Q3 24
3.0%
11.2%
Q2 24
5.2%
6.6%
Cash Conversion
ALGN
ALGN
DXCM
DXCM
Q1 26
1.34×
Q4 25
1.64×
1.10×
Q3 25
3.33×
2.33×
Q2 25
1.03×
1.69×
Q1 25
0.57×
1.74×
Q4 24
2.76×
1.99×
Q3 24
2.27×
1.48×
Q2 24
1.66×
1.95×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ALGN
ALGN

Clear Aligner$856.0M82%
CAM Services$184.1M18%

DXCM
DXCM

Segment breakdown not available.

Related Comparisons